Literature DB >> 34857438

Diagnostic delay in patients with FKRP-related muscular dystrophy.

Lauren N Coffey1, Carrie M Stephan2, M B Zimmerman3, Chyan K Decker2, Katherine D Mathews4.   

Abstract

Diagnostic journey for people with FKRP mutations participating in a dystroglycanopathy natural history study (n = 68; NCT00313677) was analyzed. Earliest symptoms and age at muscular dystrophy diagnosis were abstracted from subject-reported medical history and record review. Initial signs/symptoms were classified as chronic motor dysfunction (e.g., delayed motor milestones, weakness, falling; n = 40, 59%), elevated transaminases (n = 7, 10%), or acute/intermittent symptoms (myoglobinuria, myalgia, febrile illness-associated acute weakness; n = 21, 31%). Median time from sign/symptom onset to diagnosis was 6.5 years and differed by symptom group: 7.5 years for motor group, 9 years for acute/intermittent group, and 4 years for elevated transaminases group. The sign/symptom category that most commonly resulted in a diagnosis was chronic motor dysfunction (n = 45). Of those without clear weakness as first symptom (n = 55), 36.4% were not diagnosed with MD until weakness became apparent. Median time to diagnosis was shortest for those with febrile illness-associated acute weakness (0.25 years). Median time from first sign/symptom to MD diagnosis has decreased incrementally from 18.8 years for those with onset in the 1970s to < 10 years for symptom onset occurring after 2000. Awareness of disease presentation variability will aid in earlier diagnosis, which is increasingly important with treatments in development.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diagnosis; Diagnostic delay; Dystroglycanopathy; FKRP; Limb-girdle muscular dystrophy; Weakness

Mesh:

Substances:

Year:  2021        PMID: 34857438      PMCID: PMC8692399          DOI: 10.1016/j.nmd.2021.08.013

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  23 in total

1.  Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein.

Authors:  Céline Bouchet-Séraphin; Sandrine Vuillaumier-Barrot; Nathalie Seta
Journal:  J Neuromuscul Dis       Date:  2015

2.  Elevated liver enzymes indicating a diagnosis of limb-girdle muscular dystrophy.

Authors:  Tyler Lash; Ryan R Kraemer
Journal:  J Gen Intern Med       Date:  2014-01-23       Impact factor: 5.128

3.  Myoglobinuria and muscle pain are common in patients with limb-girdle muscular dystrophy 2I.

Authors:  K D Mathews; C M Stephan; K Laubenthal; T L Winder; D E Michele; S A Moore; K P Campbell
Journal:  Neurology       Date:  2011-01-11       Impact factor: 9.910

4.  Severe muscle damage following viral infection in patients with Fukuyama congenital muscular dystrophy.

Authors:  Terumi Murakami; Keiko Ishigaki; Seigo Shirakawa; Harumi Ikenaka; Masako Sakauchi; Makiko Osawa
Journal:  Brain Dev       Date:  2011-07-02       Impact factor: 1.961

5.  Limb-girdle muscular dystrophy in the United States.

Authors:  Steven A Moore; Christopher J Shilling; Steven Westra; Cheryl Wall; Matthew P Wicklund; Catherine Stolle; Charlotte A Brown; Daniel E Michele; Federica Piccolo; Thomas L Winder; Aaron Stence; Rita Barresi; Nick King; Wendy King; Julaine Florence; Kevin P Campbell; Gerald M Fenichel; Hansell H Stedman; John T Kissel; Robert C Griggs; Shree Pandya; Katherine D Mathews; Alan Pestronk; Carmen Serrano; Daniel Darvish; Jerry R Mendell
Journal:  J Neuropathol Exp Neurol       Date:  2006-10       Impact factor: 3.685

6.  The phenotype of limb-girdle muscular dystrophy type 2I.

Authors:  M Poppe; L Cree; J Bourke; M Eagle; L V B Anderson; D Birchall; M Brockington; M Buddles; M Busby; F Muntoni; A Wills; K Bushby
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

7.  The Classification, Natural History and Treatment of the Limb Girdle Muscular Dystrophies.

Authors:  Alexander Peter Murphy; Volker Straub
Journal:  J Neuromuscul Dis       Date:  2015-07-22

8.  Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients.

Authors:  Babi Ramesh Reddy Nallamilli; Samya Chakravorty; Akanchha Kesari; Alice Tanner; Arunkanth Ankala; Thomas Schneider; Cristina da Silva; Randall Beadling; John J Alexander; Syed Hussain Askree; Zachary Whitt; Lora Bean; Christin Collins; Satish Khadilkar; Pradnya Gaitonde; Rashna Dastur; Matthew Wicklund; Tahseen Mozaffar; Matthew Harms; Laura Rufibach; Plavi Mittal; Madhuri Hegde
Journal:  Ann Clin Transl Neurol       Date:  2018-12-01       Impact factor: 4.511

9.  Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9.

Authors:  Maggie C Walter; Volker Straub; Lindsay B Murphy; Olivia Schreiber-Katz; Karen Rafferty; Agata Robertson; Ana Topf; Tracey A Willis; Marcel Heidemann; Simone Thiele; Laurence Bindoff; Jean-Pierre Laurent; Hanns Lochmüller; Katherine Mathews; Claudia Mitchell; John Herbert Stevenson; John Vissing; Lacey Woods
Journal:  Ann Clin Transl Neurol       Date:  2020-04-28       Impact factor: 4.511

10.  Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?

Authors:  Maria Carmela Pera; Giorgia Coratti; Beatrice Berti; Adele D'Amico; Maria Sframeli; Emilio Albamonte; Roberto de Sanctis; Sonia Messina; Michela Catteruccia; Giorgia Brigati; Laura Antonaci; Simona Lucibello; Claudio Bruno; Valeria A Sansone; Enrico Bertini; Danilo Tiziano; Marika Pane; Eugenio Mercuri
Journal:  PLoS One       Date:  2020-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.